Cristina Banfi

List of Publications by Year
in descending order

119 papers	3,636 citations	117625 34 h-index	161849 54 g-index
124 all docs	124 docs citations	124 times ranked	5247 citing authors

#	Article	IF	Citations
1	Proteomic studies on apoBâ€containing lipoprotein in cardiovascular research: A comprehensive review. Mass Spectrometry Reviews, 2023, 42, 1397-1423.	5.4	3
2	Novel insights about albumin in cardiovascular diseases: Focus on heart failure. Mass Spectrometry Reviews, 2023, 42, 1113-1128.	5.4	19
3	An Optimized MRM-Based Workflow of the l-Arginine/Nitric Oxide Pathway Metabolites Revealed Disease- and Sex-Related Differences in the Cardiovascular Field. International Journal of Molecular Sciences, 2022, 23, 1136.	4.1	0
4	N-Acetylcysteine Inhibits Platelet Function through the Regeneration of the Non-Oxidative Form of Albumin. Antioxidants, 2022, 11, 445.	5.1	8
5	Prenylcysteine Oxidase 1 (PCYOX1), a New Player in Thrombosis. International Journal of Molecular Sciences, 2022, 23, 2831.	4.1	6
6	Mercaptoalbumin Is Associated with Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting. Antioxidants, 2022, 11, 702.	5.1	0
7	Oxidative Stress and Arginine/Nitric Oxide Pathway in Red Blood Cells Derived from Patients with Prediabetes. Biomedicines, 2022, 10, 1407.	3.2	1
8	Lipid Peroxidation in Atherosclerotic Cardiovascular Diseases. Antioxidants and Redox Signaling, 2021, 34, 49-98.	5.4	52
9	Multiplexed MRM-Based Proteomics Identified Multiple Biomarkers of Disease Severity in Human Heart Failure. International Journal of Molecular Sciences, 2021, 22, 838.	4.1	9
10	Sex-dependent differences in the secretome of human endothelial cells. Biology of Sex Differences, 2021, 12, 7.	4.1	21
11	In-Depth AGE and ALE Profiling of Human Albumin in Heart Failure: Ex Vivo Studies. Antioxidants, 2021, 10, 358.	5.1	4
12	Digital PCR for high sensitivity viral detection in false-negative SARS-CoV-2 patients. Scientific Reports, 2021, 11, 4310.	3.3	21
13	Cyclooxygenase-2 Glycosylation Is Affected by Peroxynitrite in Endothelial Cells: Impact on Enzyme Activity and Degradation. Antioxidants, 2021, 10, 496.	5.1	5
14	Immature Circulating SP-B, Bound to HDL, Represents an Early Sign of Smoke-Induced Pathophysiological Alterations. Biomolecules, 2021, 11, 551.	4.0	3
15	Lipid peroxidation derived reactive carbonyl species in free and conjugated forms as an index of lipid peroxidation: limits and perspectives. Redox Biology, 2021, 42, 101899.	9.0	35
16	Multiomic Approaches to Uncover the Complexities of Dystrophin-Associated Cardiomyopathy. International Journal of Molecular Sciences, 2021, 22, 8954.	4.1	4
17	Prenylcysteine oxidase 1, an emerging player in atherosclerosis. Communications Biology, 2021, 4, 1109.	4.4	13
18	Proteomics of Extracellular Vesicles: Update on Their Composition, Biological Roles and Potential Use as Diagnostic Tools in Atherosclerotic Cardiovascular Diseases. Diagnostics, 2020, 10, 843.	2.6	22

#	Article	IF	Citations
19	S-Thiolation Targets Albumin in Heart Failure. Antioxidants, 2020, 9, 763.	5.1	17
20	N-Acetyl-Cysteine Regenerates Albumin Cys34 by a Thiol-Disulfide Breaking Mechanism: An Explanation of Its Extracellular Antioxidant Activity. Antioxidants, 2020, 9, 367.	5.1	28
21	Culture Into Perfusion-Assisted Bioreactor Promotes Valve-Like Tissue Maturation of Recellularized Pericardial Membrane. Frontiers in Cardiovascular Medicine, 2020, 7, 80.	2.4	9
22	Coronary artery mechanics induces human saphenous vein remodelling <i>via</i> recruitment of adventitial myofibroblast-like cells mediated by Thrombospondin-1. Theranostics, 2020, 10, 2597-2611.	10.0	23
23	Platelets in Healthy and Disease States: From Biomarkers Discovery to Drug Targets Identification by Proteomics. International Journal of Molecular Sciences, 2020, 21, 4541.	4.1	36
24	Pro-oxidant and pro-inflammatory effects of glycated albumin on cardiomyocytes. Free Radical Biology and Medicine, 2019, 144, 245-255.	2.9	28
25	Is the placental proteome impaired in wellâ€controlled gestational diabetes?. Journal of Mass Spectrometry, 2019, 54, 359-365.	1.6	12
26	Dkk (Dickkopf) Proteins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 1330-1342.	2.4	55
27	Lipoxidation in cardiovascular diseases. Redox Biology, 2019, 23, 101119.	9.0	76
28	Immature surfactant protein-B impairs the antioxidant capacity of HDL. International Journal of Cardiology, 2019, 285, 53-58.	1.7	9
29	A proteomic approach to identify novel disease biomarkers in LCAT deficiency. Journal of Proteomics, 2019, 198, 113-118.	2.4	6
30	Association Between Haptoglobin Phenotype and Microvascular Obstruction in Patients With STEMI. JACC: Cardiovascular Imaging, 2019, 12, 1007-1017.	5.3	15
31	Reprint of: Proteomics in cardiovascular diseases: Unveiling sex and gender differences in the era of precision medicine. Journal of Proteomics, 2018, 178, 57-72.	2.4	9
32	Aortic valve cell seeding into decellularized animal pericardium by perfusion-assisted bioreactor. Journal of Tissue Engineering and Regenerative Medicine, 2018, 12, 1481-1493.	2.7	18
33	Surfactant proteins changes after acute hemodynamic improvement in patients with advanced chronic heart failure treated with Levosimendan. Respiratory Physiology and Neurobiology, 2018, 252-253, 47-51.	1.6	12
34	D-dimer is associated with arterial and venous coronary artery bypass graft occlusion. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 200-207.e3.	0.8	7
35	Proteomics in cardiovascular diseases: Unveiling sex and gender differences in the era of precision medicine. Journal of Proteomics, 2018, 173, 62-76.	2.4	21
36	Acrylate-based materials for heart valve scaffold engineering. Biomaterials Science, 2018, 6, 154-167.	5.4	12

#	Article	IF	Citations
37	Identification of DKK-1 as a novel mediator of statin effects in human endothelial cells. Scientific Reports, 2018, 8, 16671.	3.3	29
38	The application of gene silencing in proteomics: from laboratory to clinic. Expert Review of Proteomics, 2018, 15, 717-732.	3.0	5
39	Post-translational quantitation by SRM/MRM: applications in cardiology. Expert Review of Proteomics, 2018, 15, 477-502.	3.0	10
40	BDNFVal66met polymorphism: a potential bridge between depression and thrombosis. European Heart Journal, 2017, 38, ehv655.	2.2	49
41	Technological advances and proteomic applications in drug discovery and target deconvolution: identification of the pleiotropic effects of statins. Drug Discovery Today, 2017, 22, 848-869.	6.4	23
42	Diving and pulmonary physiology: Surfactant binding protein, lung fluid and cardiopulmonary test changes in professional divers. Respiratory Physiology and Neurobiology, 2017, 243, 27-31.	1.6	2
43	Exploring the biochemistry of the prenylome and its role in disease through proteomics: progress and potential. Expert Review of Proteomics, 2017, 14, 515-528.	3.0	7
44	Toward the Standardization of Mitochondrial Proteomics: The Italian Mitochondrial Human Proteome Project Initiative. Journal of Proteome Research, 2017, 16, 4319-4329.	3.7	66
45	Optimized Protocol for the Extraction of Proteins from the Human Mitral Valve. Journal of Visualized Experiments, 2017, , .	0.3	0
46	Serum Proteome in a Sporadic Amyotrophic Lateral Sclerosis Geographical Cluster. Proteomics - Clinical Applications, 2017, 11, 1700043.	1.6	8
47	A Preliminary Study on Human Placental Tissue Impaired by Gestational Diabetes: A Comparison of Gel-Based versus Gel-Free Proteomics Approaches. European Journal of Mass Spectrometry, 2016, 22, 71-82.	1.0	31
48	Normal human mitral valve proteome: A preliminary investigation by gelâ€based and gelâ€free proteomic approaches. Electrophoresis, 2016, 37, 2633-2643.	2.4	3
49	Surfactant protein B: From biochemistry to its potential role as diagnostic and prognostic marker in heart failure. International Journal of Cardiology, 2016, 221, 456-462.	1.7	21
50	The Effects of Anesthesia, Muscle Paralysis, and Ventilation on the Lung Evaluated by Lung Diffusion for Carbon Monoxide and Pulmonary Surfactant Protein B. Anesthesia and Analgesia, 2015, 120, 373-380.	2.2	17
51	Proteomics of tissue factor silencing in cardiomyocytic cells reveals a new role for this coagulation factor in splicing machinery control. Journal of Proteomics, 2015, 119, 75-89.	2.4	5
52	Atorvastatin reduces long pentraxin 3 expression in vascular cells by inhibiting protein geranylgeranylation. Vascular Pharmacology, 2015, 67-69, 38-47.	2.1	10
53	Human monocyte-derived macrophages are heterogenous: Proteomic profile of different phenotypes. Journal of Proteomics, 2015, 124, 112-123.	2.4	33
54	Data for proteomic analysis of murine cardiomyocytic HL-1 cells treated with siRNA against tissue factor. Data in Brief, 2015, 3, 117-119.	1.0	1

#	Article	IF	Citations
55	Data for proteomic analysis of Human monocyte-derived macrophages. Data in Brief, 2015, 4, 177-179.	1.0	5
56	Plasma immature form of surfactant protein type B correlates with prognosis in patients with chronic heart failure. A pilot single-center prospective study. International Journal of Cardiology, 2015, 201, 394-399.	1.7	14
57	Surfactant-Derived Proteins as Markers of Alveolar Membrane Damage in Heart Failure. PLoS ONE, 2014, 9, e115030.	2.5	32
58	The selected reaction monitoring/multiple reaction monitoring-based mass spectrometry approach for the accurate quantitation of proteins: clinical applications in the cardiovascular diseases. Expert Review of Proteomics, 2014, 11, 771-788.	3.0	36
59	A mass spectrometry-based workflow for the proteomic analysis of in vitro cultured cell subsets isolated by means of laser capture microdissection. Analytical and Bioanalytical Chemistry, 2014, 406, 2817-2825.	3.7	25
60	Opposite behavior of plasma levels surfactant protein type B and receptor for advanced glycation end products in pulmonary sarcoidosis. Respiratory Medicine, 2013, 107, 1617-1624.	2.9	8
61	Proteomic analysis of endothelial cell secretome: A means of studying the pleiotropic effects of Hmg-CoA reductase inhibitors. Journal of Proteomics, 2013, 78, 346-361.	2.4	37
62	Acute high-altitude exposure reduces lung diffusion: Data from the HIGHCARE Alps project. Respiratory Physiology and Neurobiology, 2013, 188, 223-228.	1.6	42
63	Altered iron homeostasis in an animal model of hypertensive nephropathy. Journal of Hypertension, 2013, 31, 2259-2269.	0.5	7
64	Chronic Kidney Disease in Acute Myocardial Infarction: Clinical Relevance and Novel Potential Fields of Investigation. Contributions To Statistics, 2013, , 123-136.	0.2	0
65	Silencing of FAD synthase gene in Caenorhabditis elegans upsets protein homeostasis and impacts on complex behavioral patterns. Biochimica Et Biophysica Acta - General Subjects, 2012, 1820, 521-531.	2.4	16
66	Redox Proteomics Identification of Oxidatively Modified Myocardial Proteins in Human Heart Failure: Implications for Protein Function. PLoS ONE, 2012, 7, e35841.	2.5	23
67	Cardiomyocyte death induced by ischaemic/hypoxic stress is differentially affected by distinct purinergic P2 receptors. Journal of Cellular and Molecular Medicine, 2012, 16, 1074-1084.	3.6	21
68	Statins prevent tissue factor induction by proteaseâ€activated receptorsÂ1 and 2 in human umbilical vein endothelial cells inÂvitro. Journal of Thrombosis and Haemostasis, 2011, 9, 1608-1619.	3.8	15
69	Kinetics of plasma SPB and RAGE during mechanical ventilation in patients undergoing major vascular surgery. Respiratory Physiology and Neurobiology, 2011, 178, 256-260.	1.6	12
70	Surfactant protein B and RAGE increases in the plasma during cardiopulmonary bypass: a pilot study. European Respiratory Journal, 2011, 37, 841-847.	6.7	30
71	Proteome of platelets in patients with coronary artery disease. Experimental Hematology, 2010, 38, 341-350.	0.4	37
72	Proteomic profile of differentially expressed plasma proteins from dystrophic mice and following suberoylanilide hydroxamic acid treatment. Proteomics - Clinical Applications, 2010, 4, 71-83.	1.6	30

#	Article	IF	Citations
73	Terutroban, a Thromboxane/Prostaglandin Endoperoxide Receptor Antagonist, Increases Survival in Stroke-Prone Rats by Preventing Systemic Inflammation and Endothelial Dysfunction: Comparison with Aspirin and Rosuvastatin. Journal of Pharmacology and Experimental Therapeutics, 2010, 334, 199-205.	2.5	33
74	Peroxisome Proliferator-Activated Receptor Î± Agonism Prevents Renal Damage and the Oxidative Stress and Inflammatory Processes Affecting the Brains of Stroke-Prone Rats. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 324-331.	2.5	39
75	Proteomic analysis of atherosclerotic plaque. Biomedicine and Pharmacotherapy, 2010, 64, 369-372.	5.6	9
76	Proteomic Analysis of Plasma from Patients Undergoing Coronary Artery Bypass Grafting Reveals a Protease/Antiprotease Imbalance in Favor of the Serpin Î±1-Antichymotrypsin. Journal of Proteome Research, 2010, 9, 2347-2357.	3.7	17
77	An Integrated Approach for Experimental Target Identification of Hypoxia-induced miR-210. Journal of Biological Chemistry, 2009, 284, 35134-35143.	3.4	248
78	Circulating Plasma Surfactant Protein Type B as Biological Marker of Alveolar-Capillary Barrier Damage in Chronic Heart Failure. Circulation: Heart Failure, 2009, 2, 175-180.	3.9	32
79	S 35171 exerts protective effects in spontaneously hypertensive stroke-prone rats by preserving mitochondrial function. European Journal of Pharmacology, 2009, 604, 117-124.	3.5	3
80	Proteomic analysis of human lowâ€density lipoprotein reveals the presence of prenylcysteine lyase, a hydrogen peroxideâ€generating enzyme. Proteomics, 2009, 9, 1344-1352.	2.2	41
81	Mitochondrial reactive oxygen species: a common pathway for PAR1- and PAR2-mediated tissue factor induction in human endothelial cells. Journal of Thrombosis and Haemostasis, 2009, 7, 206-216.	3.8	141
82	Stimulation of AT2 receptor exerts beneficial effects in stroke-prone rats: focus on renal damage. Journal of Hypertension, 2009, 27, 2444-2451.	0.5	113
83	On the search for glycated lipoprotein ApoAâ€I in the plasma of diabetic and nephropathic patients. Journal of Mass Spectrometry, 2008, 43, 74-81.	1.6	25
84	<i>Nonenzymatically Glycated Lipoprotein ApoAâ€I in Plasma of Diabetic and Nephropathic Patients</i>. Annals of the New York Academy of Sciences, 2008, 1126, 295-299.	3.8	19
85	Oxidized proteins in plasma of patients with heart failure: Role in endothelial damage. European Journal of Heart Failure, 2008, 10, 244-251.	7.1	49
86	Matrix metalloproteinase and heart failure: is it time to move from research to clinical laboratories?. European Heart Journal, 2007, 28, 659-660.	2.2	6
87	Rosuvastatin Treatment Prevents Progressive Kidney Inflammation and Fibrosis in Stroke-Prone Rats. American Journal of Pathology, 2007, 170, 1165-1177.	3.8	70
88	Tissue factor induction by protease-activated receptor 1 requires intact caveolin-enriched membrane microdomains in human endothelial cells. Journal of Thrombosis and Haemostasis, 2007, 5, 2437-2444.	3.8	21
89	Analysis of rosuvatatin by imaging mass spectrometry. Rapid Communications in Mass Spectrometry, 2006, 20, 3483-3487.	1.5	6
90	Proteomic analysis of membrane microdomains derived from both failing and non-failing human hearts. Proteomics, 2006, 6, 1976-1988.	2.2	46

#	Article	IF	Citations
91	Activation of NF-kB and ERK1/2 after permanent focal ischemia is abolished by simvastatin treatment. Neurobiology of Disease, 2006, 22, 445-451.	4.4	66
92	Indobufen inhibits tissue factor in human monocytes through a thromboxane-mediated mechanism. Cardiovascular Research, 2006, 69, 218-226.	3.8	29
93	Proteome of endothelial cell-derived procoagulant microparticles. Proteomics, 2005, 5, 4443-4455.	2.2	85
94	Neurohormonal activation is associated with increased levels of plasma matrix metalloproteinase-2 in human heart failure. European Heart Journal, 2005, 26, 481-488.	2.2	56
95	P2 receptors in human heart: upregulation of P2X6 in patients undergoing heart transplantation, interaction with TNFÎ± and potential role in myocardial cell death. Journal of Molecular and Cellular Cardiology, 2005, 39, 929-939.	1.9	48
96	Anti-Inflammatory Effects of AT1 Receptor Blockade Provide End-Organ Protection in Stroke-Prone Rats Independently from Blood Pressure Fall. Journal of Pharmacology and Experimental Therapeutics, 2004, 311, 989-995.	2.5	59
97	Oxidised-HDL3 induces the expression of PAI-1 in human endothelial cells. Role of p38MAPK activation and mRNA stabilization. British Journal of Haematology, 2004, 127, 97-104.	2.5	53
98	Pentoxifylline Prevents Spontaneous Brain Ischemia in Stroke-Prone Rats. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 890-895.	2.5	40
99	Effect of Interleukin-6 promoter polymorphisms in survivors of myocardial infarction and matched controls in the North and South of Europe. Thrombosis and Haemostasis, 2004, 92, 1122-1128.	3.4	42
100	The plasminogen activator inhibitor-1 -675 4G/5G genotype influences the risk of myocardial infarction associated with elevated plasma proinsulin and insulin concentrations in men from Europe: the HIFMECH Study. Journal of Thrombosis and Haemostasis, 2003, 1, 2322-2329.	3.8	52
101	Association between the Ala379Val variant of the lipoprotein associated phospholipase A2 and risk of myocardial infarction in the north and south of Europe. Atherosclerosis, 2003, 168, 283-288.	0.8	83
102	Induction of plasminogen activator inhibitor 1 by the PPARÎ± ligand, Wy-14,643, is dependent on ERK1/2 signaling pathway. Thrombosis and Haemostasis, 2003, 90, 611-619.	3.4	24
103	Vascular thrombogenicity induced by progressive LDL oxidation: protection by antioxidants. Thrombosis and Haemostasis, 2003, 89, 544-553.	3.4	22
104	Vascular thrombogenicity induced by progressive LDL oxidation: protection by antioxidants. Thrombosis and Haemostasis, 2003, 89, 544-53.	3.4	4
105	Oxidized LDLs influence thrombotic response and cyclooxygenase 2. Prostaglandins Leukotrienes and Essential Fatty Acids, 2002, 67, 169-173.	2.2	10
106	Oxidized phospholipids inhibit cyclooxygenase-2 in human macrophages via nuclear factor-Î°B/IÎ°B- and ERK2-dependent mechanisms. Cardiovascular Research, 2002, 55, 406-415.	3.8	34
107	15-Deoxy-Î”12,14-Prostaglandin J2 Inhibits Tissue Factor Expression in Human Macrophages and Endothelial Cells: Evidence for ERK1/2 Signaling Pathway Blockade. Thrombosis and Haemostasis, 2002, 88, 524-532.	3.4	33
108	Transcriptional Regulation of Plasminogen Activator Inhibitor Type 1 Gene by Insulin: Insights Into the Signaling Pathway. Diabetes, 2001, 50, 1522-1530.	0.6	69

#	Article	IF	Citations
109	Fluvastatin Inhibits Basal and Stimulated Plasminogen Activator Inhibitor 1, but Induces Tissue Type Plasminogen Activator in Cultured Human Endothelial Cells. Thrombosis and Haemostasis, 2000, 84, 59-64.	3.4	53
110	Fluvastatin inhibits basal and stimulated plasminogen activator inhibitor 1, but induces tissue type plasminogen activator in cultured human endothelial cells. Thrombosis and Haemostasis, 2000, 84, 59-64.	3.4	14
111	Very Low-Density Lipoprotein Activates Nuclear Factor-ÎºB in Endothelial Cells. Circulation Research, 1999, 84, 1085-1094.	4.5	188
112	Oxidized LDL and Lysophosphatidylcholine Stimulate Plasminogen Activator Inhibitor-1 Expression in Vascular Smooth Muscle Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1999, 19, 3025-3032.	2.4	46
113	Very Low Density Lipoproteinâ€"Mediated Signal Transduction and Plasminogen Activator Inhibitor Type 1 in Cultured HepG2 Cells. Circulation Research, 1999, 85, 208-217.	4.5	58
114	Unsaturated Fatty Acids Increase Plasminogen Activator Inhibitor-1 Expression in Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 1998, 18, 1679-1685.	2.4	96
115	Linoleic acid enhances the secretion of plasminogen activator inhibitor type 1 by HepG2 cells. Journal of Lipid Research, 1997, 38, 860-869.	4.2	25
116	Linoleic acid enhances the secretion of plasminogen activator inhibitor type 1 by HepG2 cells. Journal of Lipid Research, 1997, 38, 860-9.	4.2	18
117	Plasminogen activator inhibitor type 1 secretion by HepG2 cells. Blood Coagulation and Fibrinolysis, 1996, 7, 503.	1.0	3
118	Plasminogen Activator Inhibitor Type-1 Synthesis and mRNA Expression in HepG2 Cells Are Regulated by VLDL. Arteriosclerosis, Thrombosis, and Vascular Biology, 1996, 16, 89-96.	2.4	55
119	Apolipoprotein A-II modulates HDL remodeling in plasma. Lipids and Lipid Metabolism, 1992, 1124, 195-198.	2.6	20